Revolutionary Cancer Testing Technique Expands Across English Hospitals

A groundbreaking cancer testing technique has been authorised for large-scale implementation across hospital trusts in England, set to revolutionise patient outcomes and broaden access to life-saving genetic analysis. Whole Genome Sequencing (WGS), which identifies the types and causes of cancers by analysing a patient’s DNA, is now being introduced across the East of England following a novel stabilisation technique developed at Addenbrooke’s Hospital in Cambridge. The innovation allows cancer samples to be preserved in a dedicated preservation medium and transported at standard temperature, removing the existing obligation for high-cost minus 80 degrees Celsius cryogenic storage. The expansion, launched at the end of 2025, enables hospitals including Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital to make available the test to more patients, helping to avoid unnecessary invasive surgery and improving treatment outcomes across the region.

A Patient’s Journey to Clarity

Laraine Chung’s situation demonstrates how WGS can fundamentally alter a patient’s clinical pathway. The 63-year-old care worker from Peterborough found she had a tumour behind her left eye the previous year, but first assessments proved inconclusive about its type. Facing the likelihood of complex surgery that could threaten her eyesight and potentially affect her brain and facial structures, Chung felt the burden of an unclear path ahead. However, her access to Whole Genome Sequencing at Addenbrooke’s Hospital delivered the crucial insight her clinical team critically required to plot a better direction ahead.

The genetic analysis demonstrated that Chung’s tumour was a benign form of meningioma, a diagnosis that substantially transformed her treatment plan. Rather than proceeding with extensive and invasive surgery with prolonged recovery, she required a considerably simpler procedure. “Without the test, I would have needed much more complex surgery, and it would have involved even longer to recover,” Chung reflected. The grandmother-of-four described the moment she got her results as a deep sense of relief for both herself and her family, knowing that her vision could be preserved and her ordeal considerably reduced.

The Science Behind the Advancement

Whole Genome Sequencing represents a paradigm shift in cancer diagnostics, delivering clinicians an remarkable view into the DNA composition of malignant and benign tumours alike. By analysing the entire genomic sequence of a patient’s cancer cells, WGS enables medical teams to identify not merely what type of cancer is present, but crucially, what specific genetic mutations are driving its growth. This granular understanding allows oncologists to tailor treatment strategies with remarkable precision, steering patients away from unnecessary procedures and towards treatments with the highest success rates. The technology has already demonstrated significant impact across the NHS, yet access was limited by operational challenges that the new retention approach now addresses.

How Whole Genome Sequencing Process Works

When a tissue biopsy is extracted from a patient, it contains invaluable genetic information that can guide treatment decisions. However, the genetic material within these samples deteriorates quickly, usually within hours, unless properly maintained. Traditionally, laboratories have frozen samples at negative 80 degrees Celsius, a process requiring specialist equipment and transport infrastructure not available at many hospital sites. The innovative preservation solution now used throughout the East of England preserves the genetic material chemically, enabling secure transportation at room temperature and dramatically expanding access to this transformative diagnostic service.

• Determines specific cancer types and hereditary alterations fuelling cancer development
• Facilitates personalised treatment choice informed by individual genetic profiles
• Reveals origins of malignancies of uncertain aetiology for precision treatment
• Directs clinicians away from unnecessary invasive surgical interventions

Eliminating Logistical Obstacles to Treatment

For years, the primary obstacle to implementing Whole Genome Sequencing across the NHS has not been technical expertise, but rather the logistical difficulties of moving fragile biological samples to regional testing laboratories. Many hospitals, notably those in remote or outlying locations, lack the specialised cryogenic facilities needed to maintain genetic material during transit to centres like Cambridge University Hospitals NHS Foundation Trust. This capacity shortfall has essentially established a dual-tier arrangement, where patients at properly equipped teaching hospitals access state-of-the-art testing whilst those at smaller community hospitals continue unable to utilise the same life-preserving technology. The innovative storage technique substantially resolves this inequity.

The rollout across the eastern region, commencing in late 2025, marks a pivotal point in expanding access to advanced cancer diagnostics. Hospitals including Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital, and Ipswich Hospital can now engage with genomic sequencing initiatives formerly inaccessible to them. Dr Jeffrey Rubasingham, clinical oncology consultant at King’s Lynn, stresses the transformative impact: “This removes the need for minus 80C sample freezing and specialised transport, and facilitates cutting-edge trial therapies when conventional therapies have been exhausted.” The removal of these operational barriers is poised to broaden diagnostic precision to many more patients annually.

The Room Temperature Solution

The breakthrough preservation technique, created at Addenbrooke’s Hospital, employs a chemical stabilising solution that protects genetic material from degradation without requiring cryogenic storage. Rather than freezing samples at −80°C, tissue biopsies are submerged in this medium, which halts the progressive degradation of biological information whilst permitting safe transportation at ambient room temperature. This sophisticated advancement removes the necessity of high-cost preservation apparatus and expert delivery providers, significantly lowering both financial burden and operational difficulty. The solution sustains sample integrity throughout transportation, confirming that biological specimens arrives testing laboratories in ideal state for analysis, independent of journey length or duration.

• Preserves genetic material using chemical preservation rather than cryogenic freezing
• Allows safe sample transport at room temperature across healthcare facilities
• Removes need for costly freezing apparatus and specialised logistics
• Preserves genetic stability throughout extended transit periods to laboratory facilities

National Growth and Acknowledgement

The effectiveness of the room temperature preservation approach in the East of England has sparked careful evaluation of a countrywide expansion across NHS trusts. Senior clinicians and health service leaders acknowledge the game-changing capacity of this advancement to broaden availability to genomic testing across the country. The approach’s ease of use and cost-effectiveness have received considerable endorsement from cancer specialists, who view it as critical infrastructure for contemporary cancer care. Early responses from taking-part centres has been highly favourable, with healthcare professionals documenting effortless embedding into existing workflows and significantly better patient outcomes. This forward direction indicates that in the years ahead, genome sequencing could become routine rather than a benefit available only to patients near major diagnostic facilities.

Recognition of this breakthrough extends beyond the NHS, with international cancer research bodies endorsing its significance for worldwide health systems. The innovation tackles a core issue that has long constrained diagnostic accuracy in distant and poorly-served communities. Patient advocacy groups have supported the development, highlighting how technology-related obstacles have previously created postcode lotteries in cancer treatment. Laraine Chung’s case illustrates the profound difference: her ability to undergo testing at Addenbrooke’s maintained not only her vision but also avoided unnecessarily invasive surgery. As the technique increases in uptake, health service leaders increasingly view support for preservation methods as fundamental provision, equivalent to investing in diagnostic tools.

Environmental and Medical Impact

The shift away from ultra-cold freezing technology carries substantial environmental advantages alongside clinical advantages. Ultra-low freezers operating at minus 80 degrees Celsius consume substantial electrical energy on an ongoing basis, adding significantly to hospital greenhouse gas emissions. By negating this necessity, the room temperature preservation method reduces energy consumption and associated greenhouse gas emissions across NHS trusts involved. Simultaneously, the decrease in specialist delivery services and ultra-cold logistics decreases fuel consumption and supply chain environmental impact. These environmental gains complement the clinical benefits, illustrating how healthcare innovation can at the same time enhance patient care and sustainability objectives, positioning cancer services with NHS sustainability pledges.

What This Signifies for People with Cancer

For cancer patients throughout East of England hospitals, the introduction of room temperature preservation represents a meaningful change in availability of potentially life-critical diagnostics. Previously, patients at smaller hospitals faced a locational barrier: their tissue samples degraded during transfer to centralised testing laboratories, rendering them unsuitable for WGS analysis. Now, with samples preserved in preserving solution, patients at Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital can access the equivalent advanced genetic analysis as those cared for at major research centres. This advancement directly resolves what many characterise as postcode lottery healthcare, where health outcomes were largely determined by location rather than clinical need.

The real-world impact extend beyond mere convenience. Faster, more reliable availability of WGS allows oncologists to determine exactly which cancers patients have and which targeted therapies will be most beneficial. For some patients, this accelerates diagnosis by days or weeks—vital period when cancer is advancing. Additionally, patients may qualify for advanced research trials offering experimental treatments unavailable through standard NHS pathways. Laraine Chung’s experience demonstrates the human dimension: her test results not only protected her vision but prevented her undergoing unnecessarily complex surgery and its lengthy recovery period. As the technique rolls out further, thousands more patients should benefit from similar advantages.